ENDRA Life Sciences (NDRA) Common Equity (2016 - 2026)

ENDRA Life Sciences has disclosed Common Equity across 11 years of filings, most recently posting $1.8 million for Q1 2026.

• In Q1 2026, Common Equity rose 1.94% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 1.94% YoY), while the FY2025 annual figure was $2.3 million, down 11.73% from the prior year.
• Common Equity retreated to $1.8 million in Q1 2026, from $2.3 million in the prior quarter.
• Over the last five years, Common Equity for NDRA reached as high as $13.3 million in Q2 2022 and fell as low as $171380.0 in Q3 2025.
• The 5-year median for Common Equity is $5.2 million (2023), against an average of $5.4 million.
• Annual changes were most pronounced in 2024 — Common Equity advanced 29.77% — and 2025, when it slumped 97.41%.
• A 5-year view of Common Equity shows it stood at $7.2 million in 2022, then retreated by 21.45% to $5.7 million in 2023, then sank by 54.76% to $2.6 million in 2024, then retreated by 11.73% to $2.3 million in 2025, then declined by 20.94% to $1.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $1.8 million, $2.3 million, and $171380.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.